Compare CTRN & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTRN | LCTX |
|---|---|---|
| Founded | 1946 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 382.6M | 391.1M |
| IPO Year | 2005 | 1996 |
| Metric | CTRN | LCTX |
|---|---|---|
| Price | $45.28 | $1.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $52.00 | $5.33 |
| AVG Volume (30 Days) | 92.5K | ★ 1.0M |
| Earning Date | 06-02-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $753,079,000.00 | $14,556,000.00 |
| Revenue This Year | $7.76 | $109.40 |
| Revenue Next Year | $5.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 0.69 | ★ 53.24 |
| 52 Week Low | $18.75 | $0.40 |
| 52 Week High | $56.78 | $2.09 |
| Indicator | CTRN | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.03 | 51.14 |
| Support Level | $42.06 | $1.56 |
| Resistance Level | $48.59 | $1.82 |
| Average True Range (ATR) | 2.81 | 0.07 |
| MACD | 0.17 | 0.01 |
| Stochastic Oscillator | 49.02 | 70.00 |
Citi Trends Inc is a retailer of urban fashion apparel and accessories in the United States. The company offers apparel, including fashion sportswear for men and women, as well as children, such as newborns, infants, toddlers, boys, and girls; accessories comprising handbags, jewelry, footwear, belts, intimate apparel, scrubs, and sleepwear; and functional and decorative home products, as well as beauty products, books and toys.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.